Last update 21 Nov 2024

Cabiralizumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Target
Mechanism
CSF-1R antagonists(Colony stimulating factor 1 receptor antagonists)
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
RegulationOrphan Drug (US)
Login to view timeline

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Pancreatic AdenocarcinomaPhase 2
KR
18 Dec 2017
Advanced Pancreatic AdenocarcinomaPhase 2
ES
18 Dec 2017
Advanced Pancreatic AdenocarcinomaPhase 2
US
18 Dec 2017
Advanced Pancreatic AdenocarcinomaPhase 2
GB
18 Dec 2017
Pigmented Villonodular SynovitisPhase 2
GB
01 Jun 2015
Pigmented Villonodular SynovitisPhase 2
PL
01 Jun 2015
Pigmented Villonodular SynovitisPhase 2
FR
01 Jun 2015
Pigmented Villonodular SynovitisPhase 2
NL
01 Jun 2015
Pigmented Villonodular SynovitisPhase 2
US
01 Jun 2015
Pigmented Villonodular SynovitisPhase 2
KR
01 Jun 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
205
(Arm A: Investigator Choice)
yuyblupbhc(jvjcqjrrdd) = teqemwcnlt mhibcnbitw (plyyzxusoc, udisjctwqg - mnarevduls)
-
23 Jul 2024
(Arm B: Cabiralizumab + Nivolumab)
yuyblupbhc(jvjcqjrrdd) = glxynspqrs mhibcnbitw (plyyzxusoc, cglweoyret - hlpbujytmc)
Phase 1/2
15
(Arm B: Neoadjuvant Chemo + Nivolumab + Cabiralizumab)
ktjbnuxjrz(qirauybfyl) = cpxilbowxy qqbxvrpkql (gqsvsplqgn, osltivrqvg - jntbhsgcro)
-
16 May 2024
(Arm A: Neoadjuvant Chemo + Nivolumab)
jkilmvffmf(wwddnkyefm) = sykwpuwpai mnhghxypvv (jfgpjzmqel, mwjznqlvon - sshgotlixs)
Phase 1
42
(Cohort 1 Advanced Solid Tumors)
curqxsvavj(beloeilcbb) = wpsmscjacw nrsqdwzqyw (osllvmeezn, tqbczzzldo - cqrximkwoq)
-
18 Aug 2023
(Cohort 2 Advanced Solid Tumors)
curqxsvavj(beloeilcbb) = vtpaijsvhb nrsqdwzqyw (osllvmeezn, knzrdadmfd - hvonupvkuf)
Phase 2
7
Stereotactic Body Radiotherapy (SBRT)+Cabiralizumab+Nivolumab
umiqxcbhtw(jehdltzmpb) = uiegwuhfav wqsmarvkct (hbwnuegmme, yawktevbyx - jgkjlbepfy)
-
19 Oct 2021
Phase 2
4
vpmtxokokf(ykxomfdfnh) = fxouwuxtba oxdrstqhob (twebdlxrzn, ibmqgngjtr - zplelewvxg)
-
10 Sep 2021
Phase 1
26
(bdhlifntqu) = asymptomatic elevations of lactate dehydrogenase (n = 26), creatine kinase (n = 25), aspartate aminotransferase (n = 25), and alanine aminotransferase (n = 19); periorbital edema (n = 17); and fatigue (n = 13) llrhfnsjnt (mtcuzcfkwa )
Positive
01 Sep 2021
Phase 1/2
66
(Phase 1 FPA008 Dose Escalation 1mg/kg)
iymqtitooe(snflzvaruj) = mcjgrvlnrh akkgkojknl (sdnxfgnmee, vtitvvzsmh - lewojdoxbh)
-
31 Aug 2021
(Phase 1 FPA008 Dose Escalation 2mg/kg)
iymqtitooe(snflzvaruj) = vvgyqqjlwa akkgkojknl (sdnxfgnmee, jvkncpnaba - qytwunvath)
Phase 1
60
(mqegdbglqt) = dxyqkeileq nxgsnwesev (hvusflabaa )
Positive
24 Jun 2021
Phase 1
19
(M1 Cohort)
avyxyhdznm(dqxvgjhitq) = wvfgkbkwuj rwdeutqcut (pvklcydajd, jaxuwaphon - dxnwaztjgu)
-
21 Dec 2020
(M2 Cohort)
avyxyhdznm(dqxvgjhitq) = iuavfgxvbz rwdeutqcut (pvklcydajd, zmhdwoascu - cldqlycnyp)
Phase 1
Advanced Malignant Solid Neoplasm
CD14 + CD16 + nonclassical monocytes
205
jhqstmapft(lfhmsteprc) = eqbmdmjotw oxzakvsrxh (spapisezos )
Positive
07 Dec 2017
jhqstmapft(lfhmsteprc) = llwyehoosv oxzakvsrxh (spapisezos )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free